PhytoMedical Technologies, Inc.
(Symbol: PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and commercialization of innovative pharmaceutical compounds targeting cancer and hematologic disorders.

CANCER
PhytoMedical is developing a new class of agents designed to bind to DNA and kill cancer cells.

Scientists are testing and synthesizing anti-tumor agents with a ‘cytotoxic’ or poisonous affinity for cancer cells that are designed to bind more tightly to DNA than conventional drugs. DNA is the blueprint of life for the cancer cell, and such binding stops its replication which prevents the growth of the cancer cell and leads to its ultimate death.

Read More

4.15.10
PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Drug Candidate
PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of 'D11B', an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.